|
US5525338A
(en)
|
1992-08-21 |
1996-06-11 |
Immunomedics, Inc. |
Detection and therapy of lesions with biotin/avidin conjugates
|
|
US5223242A
(en)
|
1985-11-05 |
1993-06-29 |
The General Hospital Corporation |
Negatively charged specific affinity reagents
|
|
US4902505A
(en)
|
1986-07-30 |
1990-02-20 |
Alkermes |
Chimeric peptides for neuropeptide delivery through the blood-brain barrier
|
|
US5166320A
(en)
|
1987-04-22 |
1992-11-24 |
University Of Connecticut |
Carrier system and method for the introduction of genes into mammalian cells
|
|
NZ244306A
(en)
|
1991-09-30 |
1995-07-26 |
Boehringer Ingelheim Int |
Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
|
|
US5260308A
(en)
|
1991-11-06 |
1993-11-09 |
Mayo Foundation For Medical Education And Research |
Method to increase permeability of the blood-nerve/brain barriers to proteins
|
|
US5620675A
(en)
|
1992-06-23 |
1997-04-15 |
Diatech, Inc. |
Radioactive peptides
|
|
US5326770A
(en)
|
1992-07-17 |
1994-07-05 |
The Du Pont Merck Pharmaceutical Company |
Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
|
|
DE4311651A1
(de)
|
1993-04-08 |
1994-10-13 |
Boehringer Ingelheim Int |
Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
|
|
US5482698A
(en)
|
1993-04-22 |
1996-01-09 |
Immunomedics, Inc. |
Detection and therapy of lesions with biotin/avidin polymer conjugates
|
|
DE4418965A1
(de)
|
1994-05-31 |
1995-12-07 |
Boehringer Ingelheim Int |
Verfahren zum Einbringen von Nukleinsäure in höhere eukaryotische Zellen
|
|
US5902726A
(en)
|
1994-12-23 |
1999-05-11 |
Glaxo Wellcome Inc. |
Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
|
|
US6022897A
(en)
|
1995-04-25 |
2000-02-08 |
The Salk Institute For Biological Studies |
Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
|
|
US6413994B1
(en)
|
1999-02-22 |
2002-07-02 |
The Salk Institute For Biological Studies |
Modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
|
|
US5939442A
(en)
|
1995-06-07 |
1999-08-17 |
The Salk Institute For Biological Studies |
Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
|
|
US5780010A
(en)
|
1995-06-08 |
1998-07-14 |
Barnes-Jewish Hospital |
Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system
|
|
US5958371A
(en)
|
1995-06-08 |
1999-09-28 |
Barnes-Jewish Hospital |
Site specific binding system, nuclear imaging compositions and methods
|
|
US5690907A
(en)
|
1995-06-08 |
1997-11-25 |
The Jewish Hospital Of St. Louis |
Avidin-biotin conjugated emulsions as a site specific binding system
|
|
GB9604242D0
(en)
|
1996-02-28 |
1996-05-01 |
Glaxo Wellcome Inc |
Chemical compounds
|
|
GB9606805D0
(en)
|
1996-03-30 |
1996-06-05 |
Glaxo Wellcome Inc |
Medicaments
|
|
US6294559B1
(en)
|
1996-05-02 |
2001-09-25 |
Merck & Co., Inc. |
Antiproliferative agents associated with peroxisome proliferator activated receptors gamma1 and gamma2
|
|
US6200955B1
(en)
|
1996-06-11 |
2001-03-13 |
Commonwealth Biotechnologies, Inc. |
Heparin binding peptides
|
|
CA2276288A1
(en)
|
1996-12-31 |
1998-07-09 |
Laszlo Nagy |
Treatment of disease states which result from neoplastic cell proliferation using ppar-gamma activators and compositions useful therefor
|
|
US6060515A
(en)
|
1997-01-24 |
2000-05-09 |
The Regents Of The University Of California |
Treatment of skin conditions by use of PPARα activators
|
|
US5814647A
(en)
|
1997-03-04 |
1998-09-29 |
Board Of Regents, The University Of Texas System |
Use of troglitazone and related compounds for the treatment of the climacteric symptoms
|
|
US5925657A
(en)
|
1997-06-18 |
1999-07-20 |
The General Hospital Corporation |
Use of PPARγ agonists for inhibition of inflammatory cytokine production
|
|
CA2295930C
(en)
|
1997-07-24 |
2010-12-14 |
Yamanouchi Pharmaceutical Co., Ltd. |
Pharmaceutical compositions having cholesterol-lowering effect
|
|
US6342507B1
(en)
|
1997-09-05 |
2002-01-29 |
Isotechnika, Inc. |
Deuterated rapamycin compounds, method and uses thereof
|
|
AU9696198A
(en)
|
1997-10-17 |
1999-05-10 |
Aventis Pharmaceuticals Products Inc. |
Therapeutic uses of quinoline derivatives
|
|
US6242196B1
(en)
|
1997-12-11 |
2001-06-05 |
Dana-Farber Cancer Institute |
Methods and pharmaceutical compositions for inhibiting tumor cell growth
|
|
US6083486A
(en)
|
1998-05-14 |
2000-07-04 |
The General Hospital Corporation |
Intramolecularly-quenched near infrared fluorescent probes
|
|
GB9822473D0
(en)
|
1998-10-16 |
1998-12-09 |
Glaxo Group Ltd |
Chemical compounds
|
|
US6468996B1
(en)
|
1998-10-21 |
2002-10-22 |
Novo Nordisk A/S |
Substituted hetero-polycyclic compounds as PPARα and PPARγ activators
|
|
GB9824614D0
(en)
|
1998-11-11 |
1999-01-06 |
Glaxo Group Ltd |
Chemical compounds
|
|
US6713514B1
(en)
|
1999-04-19 |
2004-03-30 |
Lexicon Pharmaceuticals, Inc. |
PPAR-γ agonists as agents for the treatment of type II diabetes
|
|
JP4618845B2
(ja)
|
1999-06-09 |
2011-01-26 |
杏林製薬株式会社 |
ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
|
|
AU770870B2
(en)
|
1999-06-18 |
2004-03-04 |
Merck & Co., Inc. |
Arylthiazolidinedione and aryloxazolidinedione derivatives
|
|
GB9914977D0
(en)
|
1999-06-25 |
1999-08-25 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB9919413D0
(en)
|
1999-08-18 |
1999-10-20 |
Zeneca Ltd |
Chemical compounds
|
|
EP1243266A4
(en)
|
1999-11-11 |
2007-03-07 |
Kyorin Seiyaku Kk |
SOLIDS PREPARATION FOR ORAL APPLICATION
|
|
US6462046B2
(en)
|
2000-01-06 |
2002-10-08 |
Advanced Syntech, Llc |
Heterocycle derivatives as PPAR-gamma agonists
|
|
US6569879B2
(en)
|
2000-02-18 |
2003-05-27 |
Merck & Co., Inc. |
Aryloxyacetic acids for diabetes and lipid disorders
|
|
US6372250B1
(en)
|
2000-04-25 |
2002-04-16 |
The Regents Of The University Of California |
Non-invasive gene targeting to the brain
|
|
US6908908B2
(en)
|
2000-05-12 |
2005-06-21 |
Ortho-Mcneil Pharmaceutical, Inc. |
Biologically active 4H-benzo [1,4] oxazin-3-ones
|
|
WO2001087860A2
(en)
|
2000-05-12 |
2001-11-22 |
Ortho-Mcneil Pharmaceutical, Inc. |
Novel benzoxazinones as peroxisome proliferator activated receptor gamma modulators and method of treatment
|
|
PT1280784E
(pt)
|
2000-05-12 |
2007-09-03 |
Ortho Mcneil Pharm Inc |
4h-benzo [1,4] oxazin-3-onas biologicamente activas.
|
|
US7049342B2
(en)
|
2000-05-29 |
2006-05-23 |
Kyorin Pharmaceutical Co., Ltd. |
Substituted phenylpropionic acid derivatives
|
|
IL153543A0
(en)
|
2000-07-20 |
2003-07-06 |
Bristol Myers Squibb Co |
PHARMACEUTICAL COMPOSITIONS CONTAINING A COMPOUND WHICH INHIBITS OR MODULATES PPARdelta (beta) ACTIVITY
|
|
AU7705601A
(en)
|
2000-07-25 |
2002-02-05 |
Merck & Co Inc |
N-substituted indoles useful in the treatment of diabetes
|
|
EP1310494B1
(en)
|
2000-08-11 |
2012-01-25 |
Nippon Chemiphar Co., Ltd. |
PPAR (delta) ACTIVATORS
|
|
JP2004513090A
(ja)
|
2000-09-27 |
2004-04-30 |
メルク エンド カムパニー インコーポレーテッド |
糖尿病及び脂質異常症の治療のためのベンゾピランカルボン酸誘導体
|
|
AU2002211901A1
(en)
|
2000-10-10 |
2002-04-22 |
Smithkline Beecham Corporation |
Substituted indoles, pharmaceutical compositions containing such indoles and their use as PPAR-gamma binding agents
|
|
WO2002032291A2
(en)
|
2000-10-19 |
2002-04-25 |
The General Hospital Corporation |
Imaging of enzymatic activity
|
|
AU2002248221B2
(en)
|
2000-10-31 |
2006-08-17 |
Merck & Co., Inc. |
Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
|
|
UY27003A1
(es)
|
2000-11-06 |
2002-07-31 |
Schering Ag |
Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
|
|
US6838452B2
(en)
|
2000-11-24 |
2005-01-04 |
Vascular Biogenics Ltd. |
Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
|
|
AU2002233271A1
(en)
|
2000-12-20 |
2002-07-01 |
Glaxo Group Limited |
Substitued oxazoles and thiazoles as hppar alpha agonists
|
|
EP1357908A4
(en)
|
2001-01-30 |
2009-07-15 |
Merck & Co Inc |
"ACYLSULFAMIDES FOR THE TREATMENT OF FATIBILITY, DIABETES AND LIPID DISORDERS"
|
|
CA2437118A1
(en)
|
2001-02-09 |
2002-08-22 |
Merck & Co., Inc. |
2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
|
|
BR0207285A
(pt)
|
2001-02-15 |
2004-02-10 |
Pfizer Producs Inc |
Agonistas de ppar
|
|
ITRM20010136A1
(it)
|
2001-03-16 |
2002-09-16 |
Sigma Tau Ind Farmaceuti |
Composti utili per il trattamento di patologie che rispondono all'attivazione del recettore ppar-gamma.
|
|
US6548538B2
(en)
|
2001-05-22 |
2003-04-15 |
Bayer Aktiengesellschaft |
Propionic acid derivatives
|
|
JP2002368028A
(ja)
|
2001-06-13 |
2002-12-20 |
Nec Corp |
半導体パッケージ及びその製造方法
|
|
US6869967B2
(en)
|
2001-07-30 |
2005-03-22 |
Novo Nordisk A/S |
Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives
|
|
JP4179494B2
(ja)
|
2001-10-23 |
2008-11-12 |
株式会社カネカ |
ペルオキシソーム増殖剤応答性受容体リガンド剤
|
|
US20040115127A1
(en)
*
|
2002-04-12 |
2004-06-17 |
Wright Samuel D. |
Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
|
|
US6673823B2
(en)
|
2002-06-04 |
2004-01-06 |
Cedars-Sinai Medical Center |
Use of peroxisome proliferator activated receptor (PPAR)-γ ligands as a treatment for pituitary tumors and associated conditions, such as Cushing's syndrome
|
|
BR0314335A
(pt)
|
2002-09-05 |
2005-07-26 |
Novo Nordisk As |
Composto, uso do mesmo, composição farmacêutica, e métodos para o tratamento e/ou prevenção de condições mediadas por receptores nucleares, e de diabetes de tipo i, diabetes de tipo ii, tolerância prejudicada à glicose, resistência à insulina ou obesidade
|
|
US20040224995A1
(en)
*
|
2003-05-09 |
2004-11-11 |
University Of North Texas Health Science Center At Fort Worth |
Neuroprotective effects of PPARy agonists against cellular oxidative insults
|
|
US6987118B2
(en)
|
2003-05-21 |
2006-01-17 |
Pfizer Inc. |
Tetrahydroisoquinoline derivatives as PPAR-alpha activators
|
|
JP2007527416A
(ja)
|
2003-10-31 |
2007-09-27 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ペルオキシソーム増殖因子活性化受容体（ｐｐａｒ）二重作動薬として有用なフェノキシ酢酸誘導体
|
|
KR100849352B1
(ko)
|
2003-11-05 |
2008-07-29 |
에프. 호프만-라 로슈 아게 |
Ｐｐａｒ 활성화제로서 벤조-융합된 화합물
|
|
CN103030617A
(zh)
|
2004-03-16 |
2013-04-10 |
贝林格尔.英格海姆国际有限公司 |
吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
|
|
DE602004004631D1
(de)
|
2004-04-01 |
2007-03-22 |
Sanofi Aventis Deutschland |
Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika
|
|
CN1946698B
(zh)
|
2004-04-28 |
2010-12-01 |
霍夫曼-拉罗奇有限公司 |
作为ppar活化剂的吡唑苯基衍生物
|
|
AU2007299920A1
(en)
|
2006-09-19 |
2008-03-27 |
Braincells, Inc. |
PPAR Mediated Modulation of Neurogenesis
|
|
EP3053440B1
(en)
|
2007-04-11 |
2020-08-12 |
Omeros Corporation |
Compositions and methods for prophylaxis and treatment of addictions
|